Group items tagged the - Health affairs

Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...roved-in-canada-140214-4177946

health healthcare

shared by Alex Parker on 17 Feb 14 - No Cached

Alex Parker on 17 Feb 14

Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.

<div class="cArrow"> </div><div class="cContentInner">Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.</div>

...

Cancel

Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views

processandproduction.pharmaceutical-business-review.com/...ide-based-drugs-060214-4172952

health healthcare

shared by Alex Parker on 06 Feb 14 - No Cached

Alex Parker on 06 Feb 14

Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology

<div class="cArrow"> </div><div class="cContentInner">Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology</div>

...

Cancel

BioMarin selects NAGLU fusion protein drug candidate BMN 250 to treat Sanfilippo B synd... - 0 views

drugdiscovery.pharmaceutical-business-review.com/...ippo-b-syndrome-120214-4175652

health healthcare

shared by Alex Parker on 12 Feb 14 - No Cached

Alex Parker on 12 Feb 14

US-based BioMarin Pharmaceutical has selected a new drug development candidate, BMN 250, for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB (MPS IIIB).

<div class="cArrow"> </div><div class="cContentInner">US-based BioMarin Pharmaceutical has selected a new drug development candidate, BMN 250, for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB (MPS IIIB).</div>

...

Cancel

Advaxis entering into a master clinical trial agreement GRU Cancer Center - 0 views

clinicaltrials.pharmaceutical-business-review.com/...u-cancer-center-060214-4172928

health healthcare cancer

shared by Alex Parker on 07 Feb 14 - No Cached

Alex Parker on 07 Feb 14

Advaxis, a biotechnology company developing the next generation of cancer immunotherapies, has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center at Georgia Regents University to conduct four Phase I/II clinical trials.

<div class="cArrow"> </div><div class="cContentInner">Advaxis, a biotechnology company developing the next generation of cancer immunotherapies, has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center at Georgia Regents University to conduct four Phase I/II clinical trials.</div>

...

Cancel

Agenus acquires Swiss biopharmaceutical firm 4-Antibody - 0 views

drugdiscovery.pharmaceutical-business-review.com/...firm-4-antibody-140214-4177763

health healthcare cancer

shared by Alex Parker on 14 Feb 14 - No Cached

Alex Parker on 14 Feb 14

US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.

<div class="cArrow"> </div><div class="cContentInner">US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.</div>

...

Cancel

Celerion announces expansion of clinical operations to South Korea - 1 views

contractresearch.pharmaceutical-business-review.com/...-to-south-korea-050314-4189683

health healthcare

shared by Alex Parker on 05 Mar 14 - No Cached

Alex Parker on 05 Mar 14

Celerion, a leader in early clinical research, is pleased to announce the expansion of clinical operations to South Korea.

<div class="cArrow"> </div><div class="cContentInner">Celerion, a leader in early clinical research, is pleased to announce the expansion of clinical operations to South Korea.</div>

...

Cancel

Edison's EPI-743 gets FDA fast track status to treat Friedreich's Ataxia - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...reat-friedreichs-ataxia-180314

health healthcare

shared by Alex Parker on 18 Mar 14 - No Cached

Alex Parker on 18 Mar 14

US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.

<div class="cArrow"> </div><div class="cContentInner">US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.</div>

...

Cancel

Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...vt-pe-treatment-090414-4211375

Health Healthcare

shared by Alex Parker on 09 Apr 14 - No Cached

Alex Parker on 09 Apr 14

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).

<div class="cArrow"> </div><div class="cContentInner">Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).</div>

...

Cancel

EMA announces final steps for its clinical-trial data policy - 1 views

processandproduction.pharmaceutical-business-review.com/...ial-data-policy-090414-4211660

Health Healthcare

shared by Alex Parker on 09 Apr 14 - No Cached

Alex Parker on 09 Apr 14

EMA will launch a final round of targeted consultations with key stakeholders on its draft policy on proactive publication of and access to clinical-trial data at the beginning of May 2014.

<div class="cArrow"> </div><div class="cContentInner">EMA will launch a final round of targeted consultations with key stakeholders on its draft policy on proactive publication of and access to clinical-trial data at the beginning of May 2014.</div>

...

Cancel

PanOptica raises $45m to finance clinical development of anti-VEGF eye drop for wet AMD - 1 views

manufacturing.pharmaceutical-business-review.com/...rop-for-wet-amd-160414-4215489

Health Healthcare

shared by Alex Parker on 16 Apr 14 - No Cached

Alex Parker on 16 Apr 14

PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF

<div class="cArrow"> </div><div class="cContentInner">PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF</div>

...

Cancel

Health and wellness: Want to lose weight? Set the Right Time For breakfast and Dinner - 0 views

doctorzbay.blogspot.in/...weight-set-right-time-for.html

calorie count. loss tips calories Health weight

shared by leoreeves on 01 Apr 14 - No Cached

leoreeves on 01 Apr 14

Want to lose weight? Eat breakfast at seven.11 am and dinner at 6:14 pm

<div class="cArrow"> </div><div class="cContentInner">Want to lose weight? Eat breakfast at seven.11 am and dinner at 6:14 pm</div>

...

Cancel

Valeant, Ackman sign deal to acquire Botox-maker Allergan for $45bn - 1 views

manufacturing.pharmaceutical-business-review.com/...lergan-for-45bn-230414-4218796

Health Healthcare

shared by Alex Parker on 23 Apr 14 - No Cached

Alex Parker on 23 Apr 14

PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.</div>

...

Cancel

Top 5 dieting and exercise apps - 1 views

www.cbronline.com/...ting-and-exercise-apps-4220902

Health Healthcare

shared by Alex Parker on 29 Apr 14 - No Cached

Alex Parker on 29 Apr 14

Combat the Easter chocolate binge with our selection of healthy eating and exercise apps. Easter has come and gone, leaving many of us with either a mountain of chocolate or a pile of empty boxes and a rather enlarged waistline.

<div class="cArrow"> </div><div class="cContentInner">Combat the Easter chocolate binge with our selection of healthy eating and exercise apps. Easter has come and gone, leaving many of us with either a mountain of chocolate or a pile of empty boxes and a rather enlarged waistline.</div>

...

Cancel

Gaining Back My Good Health - 1 views

Due to my very hectic schedule at work there were several times that I skipped some meals and ate mostly canned foods or those that have preservatives. I thought it would not affect my health beca...

Dieticians

started by Edgar Anderson on 30 Aug 13 no follow-up yet

Quality Bed that Contributes to Healthy Living - 1 views

I like my new Craftmatic bed! I am having a quality sleep every night because I am sleeping on my new Craftmatic bed. It really helps me every time my back sores. Its amazing adjustability allows m...

Craftmatic adjustable beds

started by Craftmatic Adjustable Beds on 16 May 11 no follow-up yet

Natural Skin Care Products - 1 views

I always want my skin to look fair and natural. I have been using many skin care products, yet, I obtain no change. My skin did not even improve. I am looking for a natural skin care product that...

natural skin care

started by Natural Skincare on 14 Sep 11 no follow-up yet

Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals - 1 views

otc.pharmaceutical-business-review.com/...pharmaceuticals-200314-4200767

health healthcare cancer

shared by Alex Parker on 24 Mar 14 - No Cached

Alex Parker on 24 Mar 14

PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.</div>

...

Cancel

Goodwin, Aspyrian partner for cGMP manufacturing of new antibody drug conjugate - 1 views

manufacturing.pharmaceutical-business-review.com/...-drug-conjugate-250314-4203321

health healthcare

shared by Alex Parker on 26 Mar 14 - No Cached

Alex Parker on 26 Mar 14

PBR Staff Writer Published 25 March 2014 US-based Goodwin Biotechnology has entered into an agreement with Aspyrian Therapeutics for the technology transfer, process development, scale-up, and cGMP manufacturing of a new Antibody Drug Conjugate (ADC) for use in Phase I clinical trials.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 25 March 2014 US-based Goodwin Biotechnology has entered into an agreement with Aspyrian Therapeutics for the technology transfer, process development, scale-up, and cGMP manufacturing of a new Antibody Drug Conjugate (ADC) for use in Phase I clinical trials.</div>

...

Cancel

Boot Camp for Teenagers UK - 3 views

www.bootcampattheplace.co.uk/teenagers.html

camp for teenagers uk boot

shared by stuartspindlow2 on 25 Aug 14 - No Cached

stuartspindlow2 on 25 Aug 14

A Boot camp is considered to be a perfect place for getting effective health training for all ages. Our Boot camp for teenagers UK focuses on good exercise programs combined with the ultimate nutrition.

<div class="cArrow"> </div><div class="cContentInner">A Boot camp is considered to be a perfect place for getting effective health training for all ages. Our Boot camp for teenagers UK focuses on good exercise programs combined with the ultimate nutrition.</div>

...

Cancel

Bootcamp holidays in UK - 2 views

www.bootcampattheplace.co.uk/holidays.html

boot camp holidays uk

shared by stuartspindlow2 on 23 Jul 14 - No Cached

stuartspindlow2 on 23 Jul 14

Making holidays all around the world is undoubtedly a good and entertaining thing to do. But how about a healthy Bootcamp holidays in UK? Surely, it would be better as one can get to see life through a healthy window.

<div class="cArrow"> </div><div class="cContentInner">Making holidays all around the world is undoubtedly a good and entertaining thing to do. But how about a healthy Bootcamp holidays in UK? Surely, it would be better as one can get to see life through a healthy window.</div>

...

Cancel

Group items tagged

Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views

Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views

BioMarin selects NAGLU fusion protein drug candidate BMN 250 to treat Sanfilippo B synd... - 0 views

Advaxis entering into a master clinical trial agreement GRU Cancer Center - 0 views

Agenus acquires Swiss biopharmaceutical firm 4-Antibody - 0 views

Celerion announces expansion of clinical operations to South Korea - 1 views

Edison's EPI-743 gets FDA fast track status to treat Friedreich's Ataxia - 1 views

Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views

EMA announces final steps for its clinical-trial data policy - 1 views

PanOptica raises $45m to finance clinical development of anti-VEGF eye drop for wet AMD - 1 views

Health and wellness: Want to lose weight? Set the Right Time For breakfast and Dinner - 0 views

Valeant, Ackman sign deal to acquire Botox-maker Allergan for $45bn - 1 views

Top 5 dieting and exercise apps - 1 views

Gaining Back My Good Health - 1 views

Quality Bed that Contributes to Healthy Living - 1 views

Natural Skin Care Products - 1 views

Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals - 1 views

Goodwin, Aspyrian partner for cGMP manufacturing of new antibody drug conjugate - 1 views

Boot Camp for Teenagers UK - 3 views

Bootcamp holidays in UK - 2 views

Related searches